REGENXBIO (NASDAQ:RGNX - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at Chardan Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $52.00 price target on the biotechnology company's stock. Chardan Capital's target price suggests a potential upside of 441.10% from the stock's previous close.
Other equities analysts have also recently issued research reports about the company. HC Wainwright decreased their price objective on REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, March 17th. The Goldman Sachs Group decreased their price target on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Wall Street Zen raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a report on Tuesday, March 18th. Finally, Morgan Stanley boosted their target price on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.63.
Check Out Our Latest Stock Analysis on RGNX
REGENXBIO Price Performance
NASDAQ RGNX opened at $9.61 on Monday. The company has a market cap of $482.04 million, a P/E ratio of -1.91 and a beta of 1.09. The stock has a 50-day moving average of $8.10 and a two-hundred day moving average of $7.92. REGENXBIO has a 1-year low of $5.04 and a 1-year high of $15.36.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.41 by ($0.29). The business had revenue of $89.01 million for the quarter, compared to analysts' expectations of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. On average, analysts anticipate that REGENXBIO will post -4.84 EPS for the current fiscal year.
Insider Activity at REGENXBIO
In other news, Director Kenneth T. Mills sold 20,602 shares of REGENXBIO stock in a transaction on Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the transaction, the director now directly owns 475,103 shares of the company's stock, valued at $3,758,064.73. The trade was a 4.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 12.79% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of RGNX. FNY Investment Advisers LLC purchased a new position in shares of REGENXBIO during the first quarter worth about $35,000. Brooklyn Investment Group increased its stake in REGENXBIO by 163.7% in the 1st quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock valued at $40,000 after buying an additional 3,466 shares during the period. KLP Kapitalforvaltning AS purchased a new position in REGENXBIO during the 4th quarter worth $54,000. Pallas Capital Advisors LLC purchased a new position in REGENXBIO during the 1st quarter worth $74,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of REGENXBIO in the 4th quarter worth $79,000. 88.08% of the stock is owned by hedge funds and other institutional investors.
About REGENXBIO
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
